You are here

Article Text

Article menu
Download PDFPDF
Therapeutics
Malaria vaccine was safe for infants and did not interfere with the immunogenicity of coadministered antigens

https://doi.org/10.1136/ebm.14.3.87

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    STUDY DESIGN

    Design:

    randomised controlled trial. ClinicalTrials.gov NCT00289185.

    Allocation:

    concealed.*

    Blinding:

    blinded (parents, healthcare providers, investigators, data collectors, outcome assessors, and data analysts).*

    STUDY QUESTION

    Setting:

    hospital in Bagamoyo, Tanzania.

    Patients:

    340 infants 6–10 weeks of age (mean age 8 wks, 52% girls) who had been born at 36–42 weeks of gestation weighing ⩾2500 g. Infants were excluded if they were born to mothers positive for HIV or hepatitis B virus, had congenital malformations, or were same-sex twins.

    Intervention:

    3 doses of the RTS,S/AS02D malaria and hepatitis B vaccine (n = 170) or a hepatitis B vaccine only (n = 170) at 8, 12, and 16 weeks of age. All infants also received vaccines against diphtheria, tetanus, pertussis, and Haemophilus influenzae type B, normally provided by the World Health Organization’s Expanded Program on Immunization (EPI). …

    View Full Text

    Footnotes

    • Source of funding: Program for Appropriate Technology in Health (PATH) Malaria Vaccine Initiative and GlaxoSmithKline Biologicals.